MIND Foundation gGmbH Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2021
NCT04670081
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

MIND Foundation gGmbH

Active Ingredients

Drugs in Phase 2 Trials (2)

nicotinamide (1 trial)

psilocybin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Treatment-Resistant (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2